The year is ending on a sour note for plaintiffs in a string of lawsuits accusing Eli Lilly & Co. of misrepresenting the withdrawal risks of its blockbuster antidepressant, Cymbalta.
After a failed bid to consolidate more than two dozen individual Cymbalta suits in California, last week plaintiffs lawyers at Baum, Hedlund, Aristei & Goldman PC failed to persuade a judge to certify a parallel class action brought by Cymbalta patients in California, Massachusetts, Missouri and New York. U.S. District Judge Stephen Wilson in Los Angeles ruled Dec. 18 that the plaintiffs couldn’t establish damages on a classwide basis, finding their damages theory both “novel” and “highly flawed.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
